CD8A and neoplasm: We, then, performed intraperitoneal (i.p.)injection of TALL-104, CD8+ human Cytotoxic T cells (CTLs), before treating with anti-PD-1 therapy (pembrolizumab) i.p. twice weekly for 24 days to determine the effects of the therapy on tumor growth (Figure 1A).